Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
NCT ID: NCT00957905
Last Updated: 2017-03-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
36 participants
INTERVENTIONAL
2009-06-30
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
NCT00080990
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00042874
Flavopiridol in Treating Patients With Refractory Cancer
NCT00019344
Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
NCT00070239
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate the antitumor efficacy of the combination of flavopiridol and oxaliplatin with or without 5-FU and leucovorin in patients with relapsed or refractory GCT. The necessity of 5-FU and leucovorin to the combination will also be indirectly tested in this study.
SECONDARY OBJECTIVES:
I. To further evaluate the safety of flavopiridol in combination with oxaliplatin with or without 5-fluorouracil and leucovorin in patients with refractory or relapsed GCT.
II. To evaluate the time to tumor response (TTR) and progression-free survival for patients with refractory or relapsed GCT treated with flavopiridol in combination with oxaliplatin with or without 5-fluorouracil and leucovorin.
III. To explore the association between treatment response and p21, p53 and apoptotic markers.
OUTLINE: Patients are initially enrolled in part A (closed to accrual as of 11/15/2010). Depending on response to treatment, additional patients may be enrolled in part B.
PART A (alvocidib and oxaliplatin) (closed to accrual as of 11/15/2010): Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
PART B (alvocidib and FOLFOX): Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Tumor tissue samples may be collected periodically for further laboratory analysis.
After completion of study treatment, patients are followed up every 4-8 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A (alvocidib and oxaliplatin)
Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
Alvocidib Hydrochloride
Given IV
Oxaliplatin
Given IV
Part B (alvocidib and FOLFOX)
Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
Alvocidib Hydrochloride
Given IV
Fluorouracil
Given IV
Leucovorin Calcium
Given IV
Oxaliplatin
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alvocidib Hydrochloride
Given IV
Fluorouracil
Given IV
Leucovorin Calcium
Given IV
Oxaliplatin
Given IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Seminoma or non-seminoma
* Progressive disease after prior cisplatin-based therapy AND meets 1 of the following criteria:
* Not considered to be a candidate for potentially curative therapy
* Previously treated with high-dose chemotherapy regimens
* Does not wish to undergo potentially curative high-dose therapy
* Measurable or evaluable disease, as defined by 1 of the following criteria:
* Unidimensionally measurable metastatic disease, defined as ≥ 1 malignant tumor mass that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional CT scan or MRI or as ≥ 10 mm by spiral CT scan
* Bone lesions, ascites, peritoneal carcinomatosis, miliary lesions, pleural or pericardial effusions, lymphangitis of the skin or lung, cystic lesions, or irradiated lesions are not considered measurable disease
* Patients with measurable disease only (i.e., normal tumor markers) must have ≥ 1 site of disease that has not been previously irradiated
* Elevation of alpha-fetoprotein \> 15 ng/mL and/or elevation of beta-human chorionic gonadotropin \> 2.2 mIU/L
* If tumor markers are not elevated, ≥ 1 site of measurable disease must be present
* No known untreated CNS metastasis or primary CNS tumor
* Patients who have undergone local treatment for brain metastases and whose brain metastases are demonstrated to be stable by repeat imaging studies performed ≥ 4 weeks after treatment are eligible
* Karnofsky performance status 70-100%
* ANC ≥ 1,000/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 8.0 g/dL
* Serum creatinine ≤ 2.0 times upper limit of normal (ULN)
* Total serum bilirubin ≤ 1.5 times ULN
* AST and ALT ≤ 2.5 times ULN (unless elevation is due to underlying malignancy)
* Not pregnant or nursing
* Negative pregnancy test by ultrasound
* Fertile patients must use effective contraception
* Willing and able to comply with scheduled study visits, treatment plans, laboratory tests, follow-up tests for safety or effectiveness, and other study procedures
* Mediport or Broviac access required for patients enrolled in part B of the study
* No serious active infections
* No significant (≥ grade 2) or persistent ongoing toxicity, including peripheral neuropathy, from prior therapy
* None of the following within the past 6 months:
* Myocardial infarction
* Severe/unstable angina
* Coronary/peripheral artery bypass graft
* Symptomatic congestive heart failure
* Cerebrovascular accident or transient ischemic attack
* Pulmonary embolism
* No contraindication to any of the study drugs
* No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, interfere with the interpretation of study results, and, in the judgement of the investigator, may make the patient inappropriate for study entry
* No concurrent anti-retroviral therapy for HIV-positive patients
* Recovered from prior radiotherapy or surgery
* Residual grade 1 toxicities allowed
* No prior alvocidib
* At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), immunotherapy, or radiotherapy
* More than 4 weeks since prior major surgery
* No other concurrent approved or investigational anticancer treatment, including surgery, radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or immunotherapy
* No concurrent participation in another investigational treatment clinical trial
* Concurrent participation in supportive care trials or non-treatment trials (e.g., quality of life or laboratory analysis studies) allowed
* No concurrent vitamins, antioxidants, herbal preparations, or supplements, except for a single-tablet multivitamin
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Darren Feldman
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tower Cancer Research Foundation
Beverly Hills, California, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Mayo Clinic
Rochester, Minnesota, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
UPMC-Presbyterian Hospital
Pittsburgh, Pennsylvania, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, United States
Riverview Hospital
Wisconsin Rapids, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2011-01405
Identifier Type: REGISTRY
Identifier Source: secondary_id
MSKCC-09034
Identifier Type: -
Identifier Source: secondary_id
CDR0000646950
Identifier Type: -
Identifier Source: secondary_id
09-034
Identifier Type: OTHER
Identifier Source: secondary_id
8258
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-01405
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.